Evidence map›Paper›PMID 33276062›Full record

ArticleBiochimica et biophysica acta. General subjects2021

Development of novel monoclonal antibodies and immunoassays for sensitive and specific detection of SULF1 endosulfatase.

Yi-Wei Yang, Joanna J Phillips, David M Jablons, Hassan Lemjabbar-Alaoui

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biochimica et biophysica acta. General subjects, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.3field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Yi-Wei YangThoracic Oncology Laboratory, Department of Surgery, University of California San Francisco, San Francisco, CA, USA.
Joanna J PhillipsDepartments of Neurological Surgery and Pathology, University of California San Francisco, San Francisco, CA, USA.
David M JablonsThoracic Oncology Laboratory, Department of Surgery, University of California San Francisco, San Francisco, CA, USA.
Hassan Lemjabbar-AlaouiThoracic Oncology Laboratory, Department of Surgery, University of California San Francisco, San Francisco, CA, USA. Electronic address: hassan.lemjabbar-alaoui@ucsf.edu.
University of California, San Francisco · USNeurological Surgery · US

Funding

Extracellular Sulfatases As Novel Biomarkers For Early Detection of CancerU01CA168878 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI LEMJABBAR-ALAOUI, HASSAN, PHILLIPS, JOANNA · 2012 to 2016
$2.2M
Mitigation of preanalytic factors influencing brain tumor protein phosphorylationU01CA229345 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI PHILLIPS, JOANNA · 2019 to 2023
$1.8M
Heparan sulfate proteoglycans as critical regulators of brain cancer malignancyR01NS081117 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI PHILLIPS, JOANNA · 2012 to 2016
$1.7M
NCI NIH HHS U01 CA168878NCI NIH HHS U01 CA229345NINDS NIH HHS R01 NS081117
6 · The paper itself

Abstract

backgroundCell-surface heparan sulfate proteoglycans (HSPGs) function as receptors or co-receptors for ligand binding and mediate the transmission of critical extracellular signals into cells. The complex and dynamic modifications of heparan sulfates on the core proteins are highly regulated to achieve precise signaling transduction. Extracellular endosulfatase Sulf1 catalyzes the removal of 6-O sulfation from HSPGs and thus regulates signaling mediated by 6-O sulfation on HSPGs. The expression of Sulf1 is altered in many cancers. Further studies are needed to clarify Sulf1 role in tumorigenesis, and new tools that can expand our knowledge in this field are required.

methodsWe have developed and validated novel SULF1 monoclonal antibodies (mAbs). The isotype and subclass for each of these antibodies were determined. These antibodies provide invaluable reagents to assess SULF1- tissue and blood levels by immunohistochemistry and ELISA assays, respectively.

resultsThis study reports novel mAbs and immunoassays developed for sensitive and specific human Sulf1 protein detection. Using these SULF1 mAbs, we developed an ELISA assay to investigate whether blood-derived SULF1 may be a useful biomarker for detecting cancer early. Furthermore, we have demonstrated the utility of these antibodies for Sulf1 protein detection, localization, and quantification in biospecimens using various immunoassays.

conclusionsThis study describes novel Sulf1 mAbs suitable for various immunoassays, including Western blot analysis, ELISA, and immunohistochemistry, which can help understand Sulf1 pathophysiological role. GENERAL SIGNIFICANCE: New tools to assess and clarify SULF1 role in tumorigenesis are needed. Our novel Sulf1 mAbs and immunoassays assay may have utility for such application.

Indexed as

AnimalsAntibodies, MonoclonalBiomarkers, TumorEnzyme-Linked Immunosorbent AssayHEK293 CellsHumansMiceSulfotransferasesAntibodies, MonoclonalBiomarkers, TumorSULF1 protein, humanSulfotransferasesBiomarkerCancerELISAExtracellular sulfataseHeparan sulfateImmunoassaysImmunohistochemistryMonoclonal antibodiesPlasmaSULF1Western blot

Identifiers

PMID33276062
PMCPMC7752833
OpenAlexW3109455351

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.